Randomized trial of Macitentan/Tadalafil single-tablet combination therapy for pulmonary arterial hypertension

Background - Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients. A fixed-dose combination of the ERA macitentan and PDE5i tadalafil (M/T FDC) in a once-daily, sing...

Full description

Saved in:
Bibliographic Details
Main Authors: Grünig, Ekkehard (Author) , Jansa, Pavel (Author) , Fan, Fenling (Author) , Hauser, Jakob A. (Author) , Pannaux, Matthieu (Author) , Morganti, Adele (Author) , Rofael, Hany (Author) , Chin, Kelly M. (Author)
Format: Article (Journal)
Language:English
Published: 30 January 2024
In: Journal of the American College of Cardiology
Year: 2024, Volume: 83, Issue: 4, Pages: 473-484
ISSN:1558-3597
DOI:10.1016/j.jacc.2023.10.045
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jacc.2023.10.045
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S073510972308138X
Get full text
Author Notes:Ekkehard Grünig, MD, Pavel Jansa, MD, PHD, Fenling Fan, MD, PHD, Jakob A. Hauser, MD, PHD, Matthieu Pannaux, MSC, Adele Morganti, MSC, Hany Rofael, MD, PHD, Kelly M. Chin, MD, MSCS

MARC

LEADER 00000caa a2200000 c 4500
001 1897492030
003 DE-627
005 20241205155929.0
007 cr uuu---uuuuu
008 240802s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.jacc.2023.10.045  |2 doi 
035 |a (DE-627)1897492030 
035 |a (DE-599)KXP1897492030 
035 |a (OCoLC)1475305420 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Grünig, Ekkehard  |e VerfasserIn  |0 (DE-588)112535801  |0 (DE-627)618892605  |0 (DE-576)31856694X  |4 aut 
245 1 0 |a Randomized trial of Macitentan/Tadalafil single-tablet combination therapy for pulmonary arterial hypertension  |c Ekkehard Grünig, MD, Pavel Jansa, MD, PHD, Fenling Fan, MD, PHD, Jakob A. Hauser, MD, PHD, Matthieu Pannaux, MSC, Adele Morganti, MSC, Hany Rofael, MD, PHD, Kelly M. Chin, MD, MSCS 
264 1 |c 30 January 2024 
300 |b Illustrationen 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 22. Januar 2024 
500 |a Gesehen am 02.08.2024 
520 |a Background - Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therapy is recommended for low-/intermediate-risk pulmonary arterial hypertension (PAH) patients. A fixed-dose combination of the ERA macitentan and PDE5i tadalafil (M/T FDC) in a once-daily, single tablet would simplify treatment. - Objectives - The multicenter, double-blind, adaptive phase 3 A DUE study investigated the efficacy and safety of M/T FDC vs macitentan 10 mg and vs tadalafil 40 mg monotherapies in PAH patients, including treatment-naïve and prior ERA or PDE5i monotherapy-treated patients. - Methods - World Health Organization functional class II-III patients were randomized to M/T FDC, macitentan, or tadalafil depending on their PAH treatment (treatment-naïve, ERA, or PDE5i monotherapy) at baseline. The primary endpoint was change in pulmonary vascular resistance (PVR) at week 16. - Results - In total, 187 patients were randomized to single-tablet M/T FDC (n = 108), macitentan (n = 35), or tadalafil (n = 44). PVR reduction with M/T FDC was significantly greater vs macitentan (29%; geometric mean ratio 0.71; 95% CL: 0.61-0.82; P < 0.0001) and vs tadalafil (28%; geometric mean ratio 0.72; 95% CL: 0.64-0.80; P < 0.0001). Three patients died in the M/T FDC arm (judged unrelated to treatment). Adverse events (AEs) leading to discontinuation, serious AEs, and those of special interest (anemia, hypotension, and edema) were more frequent with M/T FDC. - Conclusions - Macitentan and tadalafil FDC significantly improved PVR vs monotherapies in PAH patients, with a safety and tolerability profile consistent with the individual components. The A DUE study supports M/T FDC as a once-daily, single-tablet combination for initial therapy and escalation to double combination therapy in patients with PAH. (Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension [PAH]) [A DUE]; NCT03904693) 
650 4 |a macitentan 
650 4 |a pulmonary arterial hypertension 
650 4 |a randomized controlled trial 
650 4 |a single-tablet (fixed-dose) combination therapy 
650 4 |a tadalafil 
700 1 |a Jansa, Pavel  |e VerfasserIn  |4 aut 
700 1 |a Fan, Fenling  |e VerfasserIn  |4 aut 
700 1 |a Hauser, Jakob A.  |e VerfasserIn  |4 aut 
700 1 |a Pannaux, Matthieu  |e VerfasserIn  |4 aut 
700 1 |a Morganti, Adele  |e VerfasserIn  |4 aut 
700 1 |a Rofael, Hany  |e VerfasserIn  |4 aut 
700 1 |a Chin, Kelly M.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |a American College of Cardiology  |t Journal of the American College of Cardiology  |d New York, NY : Elsevier, 1983  |g 83(2024), 4 vom: Jan., Seite 473-484  |h Online-Ressource  |w (DE-627)266884717  |w (DE-600)1468327-1  |w (DE-576)099603837  |x 1558-3597  |7 nnas 
773 1 8 |g volume:83  |g year:2024  |g number:4  |g month:01  |g pages:473-484  |g extent:12  |a Randomized trial of Macitentan/Tadalafil single-tablet combination therapy for pulmonary arterial hypertension 
856 4 0 |u https://doi.org/10.1016/j.jacc.2023.10.045  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S073510972308138X  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20240802 
993 |a Article 
994 |a 2024 
998 |g 112535801  |a Grünig, Ekkehard  |m 112535801:Grünig, Ekkehard  |d 910000  |d 950000  |d 950900  |d 50000  |e 910000PG112535801  |e 950000PG112535801  |e 950900PG112535801  |e 50000PG112535801  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1897492030  |e 4562019859 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1897492030","note":["Online verfügbar: 22. Januar 2024","Gesehen am 02.08.2024"],"name":{"displayForm":["Ekkehard Grünig, MD, Pavel Jansa, MD, PHD, Fenling Fan, MD, PHD, Jakob A. Hauser, MD, PHD, Matthieu Pannaux, MSC, Adele Morganti, MSC, Hany Rofael, MD, PHD, Kelly M. Chin, MD, MSCS"]},"relHost":[{"type":{"bibl":"periodical","media":"Online-Ressource"},"id":{"eki":["266884717"],"zdb":["1468327-1"],"issn":["1558-3597"]},"language":["eng"],"corporate":[{"role":"aut","display":"American College of Cardiology"}],"title":[{"title_sort":"Journal of the American College of Cardiology","subtitle":"JACC","title":"Journal of the American College of Cardiology"}],"titleAlt":[{"title":"JACC"}],"physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"12","year":"2024","issue":"4","volume":"83","text":"83(2024), 4 vom: Jan., Seite 473-484","pages":"473-484"},"origin":[{"dateIssuedDisp":"1983-","publisherPlace":"New York, NY ; New York, NY","publisher":"Elsevier ; American College of Cardiology","dateIssuedKey":"1983"}],"pubHistory":["1.1983 -"],"note":["Gesehen am 13.11.25","Ungezählte Beil.: Supplement"],"recId":"266884717","disp":"American College of CardiologyJournal of the American College of Cardiology"}],"person":[{"given":"Ekkehard","family":"Grünig","display":"Grünig, Ekkehard","role":"aut"},{"display":"Jansa, Pavel","family":"Jansa","given":"Pavel","role":"aut"},{"display":"Fan, Fenling","family":"Fan","given":"Fenling","role":"aut"},{"role":"aut","given":"Jakob A.","family":"Hauser","display":"Hauser, Jakob A."},{"given":"Matthieu","display":"Pannaux, Matthieu","family":"Pannaux","role":"aut"},{"display":"Morganti, Adele","family":"Morganti","given":"Adele","role":"aut"},{"role":"aut","display":"Rofael, Hany","family":"Rofael","given":"Hany"},{"role":"aut","given":"Kelly M.","family":"Chin","display":"Chin, Kelly M."}],"physDesc":[{"noteIll":"Illustrationen","extent":"12 S."}],"title":[{"title":"Randomized trial of Macitentan/Tadalafil single-tablet combination therapy for pulmonary arterial hypertension","title_sort":"Randomized trial of Macitentan/Tadalafil single-tablet combination therapy for pulmonary arterial hypertension"}],"id":{"eki":["1897492030"],"doi":["10.1016/j.jacc.2023.10.045"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"30 January 2024"}]} 
SRT |a GRUENIGEKKRANDOMIZED3020